V

Verona Pharma plc

VRNA

22.620
USD
-0.06
(-0.26%)
مغلق
حجم التداول
49,170
الربح لكل سهم
0
العائد الربحي
0
P/E
-22
حجم السوق
2,840,793,405
أصول ذات صلة
ABT
4.220
(3.98%)
110.150 USD
AZN
2.040
(2.58%)
81.200 USD
B
BNTX
-5.530
(-6.42%)
80.570 USD
GILD
0.470
(0.62%)
76.510 USD
I
INO
-0.670
(-6.28%)
10.000 USD
JNJ
2.930
(1.86%)
160.770 USD
MRK
0.680
(0.60%)
113.800 USD
MRNA
-25.020
(-20.99%)
94.160 USD
N
NVAX
-0.250
(-1.95%)
12.560 USD
PFE
0.115
(0.38%)
30.650 USD
الأخبار المقالات

العنوان: Verona Pharma plc

القطاع: Healthcare
الصناعة: Biotechnology
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.